- Home
- MFIN vs MDWD Comparison
MFIN vs MDWD Comparison
Compare MFIN & MDWD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MFIN
- MDWD
- Stock Information
- Founded
- MFIN 1995
- MDWD 2000
- Country
- MFIN United States
- MDWD Israel
- Employees
- MFIN N/A
- MDWD N/A
- Industry
- MFIN Finance: Consumer Services
- MDWD Medicinal Chemicals and Botanical Products
- Sector
- MFIN Finance
- MDWD Health Care
- Exchange
- MFIN Nasdaq
- MDWD Nasdaq
- Market Cap
- MFIN 190.0M
- MDWD 184.8M
- IPO Year
- MFIN 1996
- MDWD 2014
- Fundamental
- Price
- MFIN $8.92
- MDWD $19.45
- Analyst Decision
- MFIN
- MDWD Strong Buy
- Analyst Count
- MFIN 0
- MDWD 1
- Target Price
- MFIN N/A
- MDWD $25.00
- AVG Volume (30 Days)
- MFIN 41.1K
- MDWD 78.0K
- Earning Date
- MFIN 02-18-2025
- MDWD 03-20-2025
- Dividend Yield
- MFIN 4.95%
- MDWD N/A
- EPS Growth
- MFIN N/A
- MDWD N/A
- EPS
- MFIN 1.69
- MDWD N/A
- Revenue
- MFIN $293,257,000.00
- MDWD $19,720,000.00
- Revenue This Year
- MFIN N/A
- MDWD $10.15
- Revenue Next Year
- MFIN $11.69
- MDWD $25.62
- P/E Ratio
- MFIN $5.26
- MDWD N/A
- Revenue Growth
- MFIN 18.48
- MDWD N/A
- 52 Week Low
- MFIN $6.48
- MDWD $11.04
- 52 Week High
- MFIN $10.50
- MDWD $24.00
- Technical
- Relative Strength Index (RSI)
- MFIN 38.12
- MDWD 55.03
- Support Level
- MFIN $8.72
- MDWD $19.59
- Resistance Level
- MFIN $9.62
- MDWD $20.62
- Average True Range (ATR)
- MFIN 0.29
- MDWD 0.83
- MACD
- MFIN -0.03
- MDWD 0.02
- Stochastic Oscillator
- MFIN 2.09
- MDWD 54.60
About MFIN Medallion Financial Corp.
Medallion Financial Corp is a finance company that originates and services loans in various industries. Its operating segments include recreation, home improvement, commercial lending, medallion lending and Corporate and Other Investments. The company generates maximum revenue from the Recreation segment.
About MDWD MediWound Ltd.
MediWound Ltd is an integrated biopharmaceutical company focused on developing, manufacturing, and commercializing novel therapeutic products to address unmet medical needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications. Its first biopharmaceutical product, NexoBrid is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Its other product candidates in different stages of the pipeline include EscharEx for debridement of chronic wounds, and MW005 for the treatment of non-melanoma skin cancer. The company derives a majority of its revenue from the United States and the rest from the EU and other international markets.